Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis - Wikidata - awgldk - TriplyDB

Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis

Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis

http://www.wikidata.org/entity/Q34609585

about

Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance Free fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolism Selective Insulin Resistance in the Kidney The association between PGC-1α and Alzheimer's disease Emerging evidence for beneficial macrophage functions in atherosclerosis and obesity-induced insulin resistance Bioactive Plant Metabolites in the Management of Non-Communicable Metabolic Diseases: Looking at Opportunities beyond the Horizon Lessons from mouse models of high-fat diet-induced NAFLD Notch signaling as a novel regulator of metabolism t-10, c-12 CLA dietary supplementation inhibits atherosclerotic lesion development despite adverse cardiovascular and hepatic metabolic marker profiles Insulin signaling regulates fatty acid catabolism at the level of CoA activation How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?Nonalcoholic fatty liver disease - A multisystem disease?Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2 Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice Parameter trajectory analysis to identify treatment effects of pharmacological interventions Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism Treatment of nonalcoholic fatty liver disease: role of AMPK.Fructose: it's "alcohol without the buzz".PGC-1alpha negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb(alpha) axis.The metabolic syndrome Ablation of ARNT/HIF1beta in liver alters gluconeogenesis, lipogenic gene expression, and serum ketones Viewpoints on the way to a consensus session: where does insulin resistance start? The liver.Deficiency of oncostatin M receptor β (OSMRβ) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice.Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis A minor role for lipocalin 2 in high-fat diet-induced glucose intolerance.Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse.Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation.Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice.Mice deficient in group VIB phospholipase A2 (iPLA2gamma) exhibit relative resistance to obesity and metabolic abnormalities induced by a Western diet.Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia FoxO1 links hepatic insulin action to endoplasmic reticulum stress.Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state.Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B.Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome

P2860

Q24648189-4F48990B-9514-4D1C-85B1-13E68D509D64 Q24810354-6320CF86-34D3-4FDD-B4B5-E4D978049FAE Q26744243-CBA0E51E-E3DE-45ED-832E-473E53C49818 Q26751165-22038A15-8F17-4A1A-BD28-9D0F74C04E58 Q26768878-9D67A7F5-1A59-41F3-9AAA-E86D6935C6E5 Q26771980-FA37F805-3DDE-4CED-8071-6FE64B8A5ED8 Q26829532-18855C81-5908-4356-BF17-E5FB14B3C2C4 Q27014152-1C31F639-16EB-4A9F-8E05-58597E0389F5 Q27324291-86A59F0F-2383-4B10-AB8A-38747C9FE979 Q27334898-B45FB806-BE03-4FA7-84C8-9BFE7FC54C81 Q28074455-2B03F6B3-F26A-46C5-B235-0B33C912C861 Q28079077-893BB7AE-8AEF-4118-8865-F00E1AFE367D Q28272571-33837EE0-42A4-45C1-B6FE-302A8A9A319E Q28507185-E3A9A1FE-D73B-4CD3-8821-6C632C981E24 Q28507512-2037A244-1515-4F9B-8821-A333FDC74A00 Q28535030-EDB8CB5A-3DEB-436F-812F-A5452F546365 Q28583188-A7FCE83C-B054-4B1C-81DE-6787AAE85160 Q28591917-CBDD1A88-4D73-4572-8EF1-87B350DD4986 Q30248230-3D2631EE-A95F-4BE7-AF50-CDD549429080 Q30428239-47A0E565-C8DF-4895-A740-ABFF3651F294 Q33564184-538D95FA-B34B-491A-91AC-47B0AE043D7D Q33569142-95046710-FAEC-4AB1-A4C1-065E033B0D6E Q33577124-E889B954-5FFA-4F2C-A36E-EFCFEE843D71 Q33610786-0A498E3E-1930-412B-8AEF-3883C35C4BC5 Q33619351-947AC6FB-C9A1-441D-AD64-73799EADA137 Q33688639-5EBE180E-F509-4026-AEBD-F4586C53C456 Q33734679-BFAB4A16-B288-4F7C-966D-2FCA76394683 Q33816671-C71EFE8C-A235-40A0-9BCE-79812AFD201B Q33848311-37A401D6-5E5C-4D5E-940F-09855328403F Q33865096-25A59341-8A27-46F8-97B0-895EA1183EA1 Q33867427-6859F8A5-C56F-4B38-8DD2-4BC6F99D5CB4 Q33869748-9EB6AD05-3D6A-4B40-8842-3BB6174C19E6 Q33916535-40056919-CE6D-4B46-A72A-7CBAC4508C60 Q34037347-BFEEB794-2922-45DF-8310-111C124B2E46 Q34089899-9FB72CEA-7DED-4DAD-8ADF-00FC9498A05D Q34094336-BCE88B97-97A2-43E8-92E8-FD058F0BB867 Q34132566-53B8EE59-45D5-4F7B-AD93-2761B0F6FE6E Q34155467-2CF41D30-777E-41D1-8F13-A725570AECE7 Q34212081-0C6453A2-9D56-4616-97A5-57F091C4F227 Q34227893-4565EEA4-E006-441E-8F2D-38A3D5E8DB9D

P2860

Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis

http://www.wikidata.org/entity/Q34609585

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@ast

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@en

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@nl

type

label

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@ast

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@en

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@nl

prefLabel

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@ast

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@en

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@nl

P1433

Q34609585-8C67E0D2-9908-4246-AEDC-342579BC446C

P1476

Q34609585-FD00165C-6A20-4189-A41A-51099B4DA2D3

P2093

Q34609585-125F95B4-13DF-4AEB-88B0-912C3E9D4D20

Q34609585-212F2B08-AD24-4AEB-8EE3-777215691C36

Q34609585-21AA92AA-C5CB-4183-9EA7-229C66BF4254

Q34609585-28AAB961-9EFF-4261-AB5E-CFCAFC8C2C86

Q34609585-430D33BB-CA41-42B1-95BB-03CC2EBE53EF

Q34609585-53708431-2DD4-489A-AEB0-715D7C882C17

Q34609585-689E8749-4DF4-4940-A5BB-1B6D7DEC9FC4

Q34609585-6B7FC1D1-C1C2-49F6-BAB8-A0E750D6AC41

Q34609585-787ECC2D-3FE1-449E-BACD-8CEEACF616F4

Q34609585-7D224A93-0610-4B3A-A3DD-5C4F4E4C2C78

P2860

Q34609585-0484EB83-43F5-4AE5-A1D2-F605BD60A08C

Q34609585-0889C7C5-048E-49D6-95BE-BDDDA9DC729E

Q34609585-0B0D83BE-743B-4C33-9CBA-BFF527DF938D

Q34609585-174B5328-6201-46CD-9EA8-E4B2AB0D7CE7

Q34609585-1B1DBC6B-E310-4134-801F-89CBF7E9E5ED

Q34609585-1D5092E4-326B-4150-819E-89D0AE25D059

Q34609585-29CB96C9-5431-4220-9170-E37875E4A05C

Q34609585-2B7E6C17-531B-4F72-9EC9-80D1D42CAF10

Q34609585-2C8CAF52-9697-4009-9BF9-96A0D873C4FE

Q34609585-2D041251-025B-4756-92D1-D0B056007804

P304

Q34609585-7F0769FE-9058-44EE-9FF9-05C64B06FD1C

P31

Q34609585-A04C3943-34A6-4EC0-B6C6-3924F1E65D0B

P356

Q34609585-EB98DD77-67A2-4519-AFF4-21A948AEB6E0

P433

Q34609585-F1BB46C2-09F8-49F2-9021-098DC1E58ED5

P478

Q34609585-5F6F0A01-77F0-4324-8BE1-D18FF75CFF4D

P50

Q34609585-044DB3D6-BA55-49B6-8841-98CC2231803C

Q34609585-A744FE0F-2577-4031-8959-96D2407E3012

P577

Q34609585-D722D110-A4CD-4445-B595-07CA977FF026

P5875

Q34609585-D2AE1D60-DEFD-4E7C-B126-34FD53500F6F

P698

Q34609585-57F45148-5478-47E2-8990-7F462C8D9E19

P921

Q34609585-41D62D7B-6E96-4F61-B265-BCBC0DA21797

Q34609585-4556EBFE-ECE3-416C-A62B-BA66F79FA236

Q34609585-687ED170-B272-4799-9640-D738974B4A5C

P932

Q34609585-43B7BE2B-5BFA-450A-AAAE-18DD80D7453F

P356

J.CMET.2007.11.013

P1433

Cell Metabolism

P1476

Hepatic insulin resistance is ...... ceptibility to atherosclerosis

@en

P2093

Antonio Hernandez-Ono

http://www.w3.org/2001/XMLSchema#string

C Ronald Kahn

http://www.w3.org/2001/XMLSchema#string

Christian Rask-Madsen

http://www.w3.org/2001/XMLSchema#string

David E Cohen

http://www.w3.org/2001/XMLSchema#string

Erez F Scapa

http://www.w3.org/2001/XMLSchema#string

George L King

http://www.w3.org/2001/XMLSchema#string

Gregory Stephanopoulos

http://www.w3.org/2001/XMLSchema#string

Henry N Ginsberg

http://www.w3.org/2001/XMLSchema#string

Joel T Haas

http://www.w3.org/2001/XMLSchema#string

Martin C Carey

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta

Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice

Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

LXRS and FXR: the yin and yang of cholesterol and fat metabolism

Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c

Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis

Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice

Banting lecture 1988. Role of insulin resistance in human disease

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

P304

125-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CMET.2007.11.013

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5603567

http://www.w3.org/2001/XMLSchema#string

P698

18249172

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

4251554

http://www.w3.org/2001/XMLSchema#string